TP53 and colorectal carcinoma: Together with the observed CRC resistance to cisplatin and oxaliplatin, the tumor suppressor p53 (known as the “guardian of the genome”) appears to be essential for CRC sensitivity to DNA-targeting drugs of different compound and mechanistic classes.